1. U.S. Food and Drug Administration Center for Drug Evaluation. Wellbutrin and Welbutrin SR NDA 018644/S-041 and 02358/S-048 Approval Letter, 2013.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020358Orig1s053.pdf, accessed December 21, 2015.
2. U.S. Food and Drug Administration Center for Drug Evaluation. Zyban NDA 20–711 Approval Letter, 1997.http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_PHARMR_P1.PDF, accessed February 6, 2016.
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Contrave NDA 20006Orig1s000 Approval Letter, 2014, accessed February 6, 2016.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000Approv.pdf.
4. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug interaction studies- study design, data analysis, implications for dosing, and labeling, 2012, accessed May 3, 2016.http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.
5. 15 Years of Clinical Experience With Bupropion HCl